Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Non-Current Debt (2016 - 2020)

Cardiff Oncology's Non-Current Debt history spans 6 years, with the latest figure at $234270.0 for Q2 2020.

  • For Q2 2020, Non-Current Debt changed N/A year-over-year to $234270.0; the TTM value through Jun 2020 reached $234270.0, changed N/A, while the annual FY2016 figure was $14.2 million, N/A changed from the prior year.
  • Non-Current Debt for Q2 2020 was $234270.0 at Cardiff Oncology, down from $12.7 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $15.6 million in Q3 2016 and bottomed at $234270.0 in Q2 2020.
  • The 3-year median for Non-Current Debt is $11.5 million (2016), against an average of $10.4 million.
  • The largest YoY upside for Non-Current Debt was 35.39% in 2016 against a maximum downside of 29.89% in 2016.
  • A 3-year view of Non-Current Debt shows it stood at $14.2 million in 2016, then decreased by 10.42% to $12.7 million in 2017, then tumbled by 98.16% to $234270.0 in 2020.
  • Per Business Quant, the three most recent readings for CRDF's Non-Current Debt are $234270.0 (Q2 2020), $12.7 million (Q1 2017), and $14.2 million (Q4 2016).